Mirador Therapeutics is a technology company.
Mirador Therapeutics has raised $400.0M across 1 funding round.
Mirador Therapeutics has raised $400.0M in total across 1 funding round.
Mirador Therapeutics is a biotechnology company developing precision medicines for patients with chronic immune-mediated inflammatory and fibrotic diseases.[1][2][3] It leverages the Mirador360™ precision development engine, which integrates advances in human genetics and data science to accelerate therapeutic programs in immunology and inflammation.[1][2][3] Launched in 2024 and based in San Diego, CA, the company has raised over $400 million from investors including ARCH Venture Partners, OrbiMed, and Fairmount Funds, serving patients underserved by current treatments through faster, data-driven drug development.[1][2][5] With 94 employees and a strong culture emphasizing trust, ambition, and excellence, Mirador reports 95% employee satisfaction, far above industry averages.[1][6]
Mirador Therapeutics was launched on March 21, 2024, founded by Mark C. McKenna, who serves as chairman and CEO.[2][3] McKenna previously led Prometheus Biosciences—acquired by Merck for $10.8 billion in 2023—where he oversaw over $1 billion in financing, the top biotech IPO of 2021, and the first precision therapeutics in immune-mediated diseases.[2][4] The company is led by several former Prometheus executives, bringing proven expertise from that success.[2][3] This team emerged from Prometheus' vantage point to tackle immunology and inflammation (I&I) with a fresh precision medicine approach, rapidly advancing multiple programs post-launch.[2][3]
Mirador stands out in biotech through its specialized focus and execution:
Recent hires like CFO Gregg Gilbert add 25+ years of biopharma finance expertise to fuel growth.[5]
Mirador rides the precision medicine wave in immunology, capitalizing on exponential advances in human genetics and machine learning to target fibrotic and inflammatory diseases where one-size-fits-all therapies fail.[1][2][3] Timing is ideal post-Prometheus' 2023 acquisition, validating genetics-driven I&I approaches amid rising demand for personalized treatments in a $100B+ market.[2][4] Favorable forces include surging investor interest in data-science biotech (evidenced by its $400M raise) and regulatory tailwinds for targeted therapies.[2][5] By scaling Prometheus' playbook, Mirador influences the ecosystem, accelerating "moonshot" innovations and attracting talent to San Diego's biotech hub.[1][3][6]
Mirador is poised to advance multiple therapeutic programs into clinical stages, leveraging its engine for first-in-class I&I medicines amid AI-biotech convergence.[1][2] Key trends like multimodal data integration and fibrotic disease breakthroughs will propel it, potentially mirroring Prometheus' path to acquisition or IPO.[2][4] Its influence may grow by redefining precision development speed, drawing more capital and partnerships—watch for Phase 1/2 data catalysts. This next-gen player builds directly on proven successes, positioning it to transform patient lives in immune-mediated diseases.[3]
Mirador Therapeutics has raised $400.0M in total across 1 funding round.
Mirador Therapeutics's investors include ARCH Venture Partners, Cambridge Innovation Capital, HealthCap, Mubadala.
Mirador Therapeutics has raised $400.0M across 1 funding round. Most recently, it raised $400.0M Series A in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $400.0M Series A | ARCH Venture Partners, Cambridge Innovation Capital, HealthCap, Mubadala |